| Name | Title | Contact Details |
|---|---|---|
Paloma Giangrande |
Chief Technology Officer | Profile |
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Pattern is building a dream team of scientists and visionaries dedicated to addressing this global problem with faster, smarter diagnostics for more precise treatment.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.
BIND Biosciences, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Abgent is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.